Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

Key Stats

Today's Range
$19.00
$19.00
50-Day Range
$18.20
$19.00
52-Week Range
$8.82
$21.86
Volume
N/A
Average Volume
1.36 million shs
Market Capitalization
$794.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Stock News Headlines

Nvidia warning urgent
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ICPT Stock Analysis - Frequently Asked Questions

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.42. The company's revenue was up 16.6% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
8/02/2023
Today
11/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
341
Year Founded
N/A

Profitability

Net Income
$221.82 million
Pretax Margin
-18.09%

Debt

Sales & Book Value

Annual Sales
$285.71 million
Book Value
$1.72 per share

Miscellaneous

Free Float
39,192,000
Market Cap
$794.77 million
Optionable
Optionable
Beta
0.88

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ICPT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners